A novel molecule of the angiotensin II receptor blocker class: Focus on olmesartan medoxomil

High Blood Pressure and Cardiovascular Prevention

Volumn 12, Issue 2, 2005, Pages 79-89

  Volpe, Massimo ^a   Trimarco, Bruno ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; TELMISARTAN; VALSARTAN;

ANGIONEUROTIC EDEMA; BILIARY TRACT DISEASE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IC 50; LIVER DISEASE; META ANALYSIS; OBESITY; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SMOKING;

EID: 24944589168     PISSN: 11209879     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151642-200512020-00004     Document Type: Review

References (62)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289 (18): 2363-9
2. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease: part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-39
4. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. New Engl J Med 2001; 345 (18): 1291-7
5. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world: Seven Countries Study Research Group. N Engl J Med 2000; 342: 1-8
6. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial (MRFIT) research group. Arch Intern Med 1992; 152: 56-64
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955-64
8. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000; 356 (9246): 1949-54
9. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profile. Am Heart J 1991; 121: 293-8
10. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (1 Pt 2): 3S-10S
11. European Society of Hypertension (ESH)/European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-1053
12. Chobanian A, Bakris G, Black H, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289: 2560-71
13. WHO. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97
15. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol. The LIFE Study Group. Lancet 2002; 359: 995-1003
16. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the (Valsartan Antihypertensive Long-term Use Evaluation) VALUE randomised trial. The VALUE trial group. Lancet 2004; 363 (9426): 2022-31
17. Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005; 19 (5): 331-9
18. Yusuf S, Sleight P, Dagenais G, et al. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE) Study Group. New Engl J Med 2000; 342: 145-53
19. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study: a randomised trial against atenolol. The LIFE study group. Lancet 2002; 359: 1004-10
20. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes: the Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group. N Engl J Med 2001; 345: 851-60
21. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes: the IRbesartan MicroAlbuminuria type 2 diabetes mellitus in hypertensive patients (IRMA2) study group. N Engl J Med 2001; 345: 870-8
22. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. The MicroAlbuminuria Reduction With VALsartan (MARVAL) study investigators. Circulation 2002; 106: 672-8
23. Volpe M. Evidence-based indications in hypertensive patients: helping doctors in the initial choice. High Blood Press Cardiovasc Prev 2004; 11 (1): 1-7
24. Chiu AT, McCall DE, Nguyen TT, et al. Discrimination of angiotensin II receptor subtypes by dithiothreitol. Eur J Pharmacol 1989; 170: 117-8
25. Chang RSL, Lotti VJ. Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol 1990; 37 (3): 347-51
26. Lin SY, Goodfriend TL. Angiotensin receptors. Am J Physiol 1970; 218: 1319-28
27. Glossman H, Baukal A, Catt KJ. Angiotensin II receptors in bovine adrenal cortex: modification of angiotensin II binding by guanyl nucleotides. J Biol Chem 1974; 294: 664-6
28. Glossman H, Baukal A, Catt KJ. Cation dependence of high-affinity angiotensin II binding to adrenal cortex receptors. Science 1974; 185: 281-3
29. Sasaki K, Yamano Y, Bardhan S, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991; 351: 230-3
30. Murphy TJ, Alexander RW, Griendling KK, et al. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-336
31. Jayadev S, Smith RD, Jagadeesh G, et al. N-linked glycosylation is required for optimal AT1a angiotensin receptor expression in COS-7 cells. Endocrinology 1999; 140: 2010-7
32. Bihoreau C, Monnot C, Davies E, et al. Mutation of Asp74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G-protein coupling. Proc Natl Acad Sci U S A 1993; 90: 5133-7
33. Shirai H, Takahashi K, Katada T, et al. Mapping of G protein coupling sites of the angiotensin II type 1 receptor. Hypertension 1995; 25: 726-30
34. Zhuo J, Alcorn D, Allen AM, et al. High resolution localization of angiotensin II receptors in rat renal medulla. Kidney Int 1992; 42: 1372-80
35. Zhuo J, Alcorn D, Harris PJ, et al. Localization and properties of angiotensin II receptors in rat kidney. Kidney Int 1993; 44 Suppl. 42: S40-6
36. Navar LG, Inscho EW, Majid SA, et al. Paracrine regulation of the renal microcirculation. Physiol Rev 1996; 76: 425-536
37. Gigante B, Rubattu S, Russo R, et al. Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Hypertension 1997; 30: 563-8
38. Vendeira P, Pignatelli D, Neves D, et al. New insights into zonal differentiation of adrenal autotransplants in the rat: an immunohistochemical study. J Endocrinol 1996; 149 (3): 497-502
39. Zhuo J, Allen AM, Yamada H, et al. Localization and properties of the angiotensin converting enzyme and angiotensin receptors in the heart. In: Lindpaintner K, Ganten D, editors. The cardiac renin-angiotensin system. New York: Future, 1994: 68
40. Kobayashi M, Furukawa Y, Chiba S. Positive chronotropic and inotropic effects of angiotensin II in the dog heart. Eur J Pharmacol 1978; 50: 17-25
41. Allen AM, McGregor DP, Chai SY, et al. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992; 32: 339-44
42. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259: H610-8
43. Schorb W, Booz GW, Dostal DE, et al. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993; 72: 1245-54
44. Sadoshima J, Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor. Circ Res 1993; 73: 413-23
45. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-8
46. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane-bound NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-23
47. Touyz RM, Chen X, Tabet F, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002; 90: 1205-13
48. Volpe M, Tocci G, Pagannone E. Activation of the renin-angiotensin- aldosterone system in heart failure. Ital Heart J 2005; 6 Suppl. 1: 16S-23S
49. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001; 19 Suppl. 1: S3-S14
50. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl 2001; 19 Suppl. 1: S21-32
51. von Bergmann K, Laeis P, Puchler K, et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 Suppl. 1: S33-40
52. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 13: 904-12
53. Puchler K, Lacis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 Suppl. 1: S41-8
54. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hypertens 2002; 16 Suppl. 2: S24-8
55. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425-32
56. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 Suppl.: S49-56
57. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-91, 318
58. Smith DHG, Dubiet R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy. Am J Cardiovasc Drugs 2005; 5 (1): 41-50
59. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens 2005; 18 (2 Pt 1): 287-94
60. Brunner H, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23 (7): 419-30
61. Mengden T, Ewald S, Kaufmann S, et al. Telemonitoring of blood pressure self measurements in the OLMETEL study. Blood Press Monit 2004; 9: 321-5
62. Heagarty T, Stefenelli T, Woittiez AJ, et al. Olmebest study: reduction of blood pressure in the treatment of patients with mild-moderate essential hypertension. Interim analysis [abstract no. 4A.6]. J Hypertens 2005; 232 Suppl. 2: 3.344-8